К документу с изложением позиции Всемирной психиатрической ассоциации по вопросу соблюдения прав пожилых людей с психическими расстройствами

Растущее число пожилых людей во всех странах мира является большой проблемой для тех, кто отвечает за продвижение, защиту и реализацию прав этой группы населения. Задача дополнительно усложняется ввиду отсутствия устоявшейся международной системы, определяющей принципы работы организаций, борющихся за права человека. Необходимость создания специфической для пожилых людей с психическими расстройствами системы особенно оправдана ввиду повышенной уязвимости этой группы населения из-за дискриминации по возрастному признаку, стигматизации, изоляции, а также инвалидизации и зависимого положения, с которыми могут столкнуться люди пожилого возраста с психическими расстройствами. В настоящей статье развивается ранее изложенная позиция Международной психогериатрической ассоциации и Секции психиатрии позднего возраста Всемирной психиатрической ассоциации. Поскольку призыв поддержать действия, направленные на борьбу за права пожилых людей, обращен ко всем организациям, текст будет представлен исполнительному комитету Всемирной психиатрической ассоциации для утверждения официальной позиции в отношении соблюдения прав пожилых людей с психическими расстройствами.

1. Alzheimer's disease facts and figures. Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23. PMID: 33756057.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.
3. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007;6(8):734–746. doi: 10.1016/s1474-4422(07)70178-3.
4. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9(11):1118–1127. doi: 10.1016/s1474-4422(10)70223-4.
5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease. Focus 2013;11(1):96–106. doi: 10.1176/appi.focus.11.1.96.
6. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018 Apr;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018.
7. Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, et al. Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 2015 Sep;138(Pt 9):2701–2715. doi: 10.1093/brain/awv199.
8. Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, Houot M, Lista S, Cacciamani F, Potier MC, et al. Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol 2018 Apr; 17(4):335–346. doi: 10.1016/S1474-4422(18)30029-2.
9. Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol 2016 Sep;15(10):1044–1053. doi: 10.1016/S1474-4422(16)30125-9.
10. Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, et al. Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum. Alzheimers Res Ther 2019 Jul 4;11(1):60. doi: 10.1186/s13195-019-0510-3.
11. Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ, Alzheimer’s Disease Neuroimaging I. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease. Neuroimage 2017 Aug 15;157:448–463. doi: 10.1016/j.neuroimage.2017.05.058.
12. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol 2021;20(6):484–496. doi: 10.1016/s1474-4422(21)00066-1.
13. Iacono D, Resnick SM, O’Brien R, Zonderman AB, An Y, Pletnikova O, Rudow G, Crain B, Troncoso JC. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent beta-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol 2014 Apr;73(4):295–304. doi: 10.1097/NEN.0000000000000052.
14. Eke CS, Jammeh E, Li X, Carroll C, Pearson S, Ifeachor E. Early Detection of Alzheimer’s Disease with Blood Plasma Proteins Using Support Vector Machines. IEEE J Biomed Health Inform 2021 Jan;25(1):218–226. doi: 10.1109/JBHI.2020.2984355.
15. Xue W, Li J, Fu K, Teng W. Differential Expression of mRNAs in Peripheral Blood Related to Prodrome and Progression of Alzheimer’s Disease. Biomed Res Int 2020;2020:4505720. doi: 10.1155/2020/4505720.
16. Fedorova YB, Zakharova NV, Bugrova AE, Indeikina MI, Brzhozovskii AG, Popov IA, Kononikhin AS, Kolykhalov IV, Gavrilova SI, Nikolaev EN. Issledovanie izmenenii proteoma plazmy krovi, assotsiirovannykh s bolezn’yu Al’tsgeimera. XVII s”ezd psikhiatrov Rossii. In: Neznanov NG, editor. Interdistsiplinarnyi podkhod k komorbidnosti psikhicheskikh rasstroistv na puti k integrativnomu lecheniyu; 2021 May 15–18; Saint-Petersburg. Saint-Petersburg: NMITs PN im. V.M. Bekhtereva; 2021. p.182–184. Russian.
17. Bazenet C, Lovestone S. Plasma biomarkers for Alzheimer’s disease: much needed but tough to find. Biomark Med 2012 Aug;6(4):441–454. doi: 10.2217/bmm.12.48.
18. Zhuravin IА, Nalivaeva NN, Kozlova DI, Kochkina EG, Fedorova YB, Gavrilova SI. The activity of blood serum cholinesterases and neprilysin as potential biomarkers of mild-cognitive impairment and Alzheimer’s disease. Zhurnal nevrologii i psikhiatrii im SS Korsakova 2015;115(12):110. doi: 10.17116/jnevro2015115112110-117. Russian.
19. Alesenko AV, Gavrilova SI, Karatasso YI, Fedorova YB, Tiganov AS. Tseramidy — potentsial’nye biomarkery bolezni Al’tsgeimera. Potentsial’naya rol’ sfingolipidov v neiropatogeneze bolezni Al’tsgeimera. Psychiatry (Moscow) 2014;(1):13–20. Russian.
20. Gavrilova SI, Volpina OM, Kolykhalov IV, Fedorova YB, Selezneva ND, Ponomareva EV, Koroev DO, Kamynina AV. Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment. Zhurnal nevrologii i psikhiatrii im SS Korsakova 2017;117(8):27. doi: 10.17116/jnevro20171178127-38. Russian.
21. Schram MT, Euser SM, de Craen AJ, Witteman JC, Frolich M, Hofman A, Jolles J, Breteler MM, Westendorp RG. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007 May;55(5):708–716. doi: 10.1111/j.1532-5415.2007.01159.x.
22. Androsova LV, Klyushnik TP, Zozulya SA, Mikhaylova NM. Leukocyteelastase and interleukins in Alzheimer’s disease. Diseases 2013;11(1):1173. Russian.
23. Klyushnik TP, Androsova LV, Mikhailova NM, Sokolov AV, Kostevich VA, Zakharova ET, Vasil’ev VB. Potentsial’nye markery bolezni Al’tsgeimera, assotsiirovannye s vospaleniem. Psychiatry (Moscow) 2014;(1):28–34. Russian.
24. Ponomareva EV, Krinsky SA, Gavrilova SI. Prognosis of amnestic mild cognitive impairment: clinical and immunological correlations. Zhurnal nevrologii i psikhiatrii im SS Korsakova 2021;121(10. Vyp. 2): 16–22. doi: 10.17116/jnevro202112110216. Russian.
25. Klyushnik TP, Zozulya SA, Androsova LV, Sarmanova ZV, Otman IN, Panteleeva GP, Oleichik IV, Kopeiko GI, Borisova OA, Abramova LI, et al. Laboratornaya diagnostika v monitoringe patsientov s endogennymi psikhozami. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016. Russian.
26. Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Med Res Rev 2021 Sep;41(5):2775–2803. doi: 10.1002/med.21722. Russian.
27. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012 Apr;48 Suppl A:3–24. doi: 10.1358/dot.2012.48(Suppl.A).1739716.
28. Hartbauer M, Hutter-Paie B, Windisch M. Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. J Neural Transm (Vienna) 2001;108(5):581–592. doi: 10.1007/s007020170058.
29. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S. Neurotrophic factor-like effect of FPF1O7O on Septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 1992;7(2):21–21.
30. Gavrilova SI, Kolykhalov IV, FedorovaYB, Selezneva ND, Kalyn YB, Roshchina IF, Odinak MM, Emelin AY, KashinAV, Gustov AV, et al. Vozmozhnosti preventivnoi terapii bolezni Al’tsgeimera: rezul’taty 3-letnego prospektivnogo sravnitel’nogo issledovaniya effektivnosti i bezopasnosti kursovoi terapii tserebrolizinom i kavintonom u pozhilykhpatsientov s sindromom myagkogo kognitivnogo snizheniya. Zhurnal nevrologii i psikhiatrii im SS Korsakova 2010;(1):68–75. Russian.
31. Gavrilova SI, Ponomareva EV, Krynskii SA, Malashenkova IK, Khailov NA, Ogurtsov DP, Chekulaeva EI, Didkovskii NA. Immunologicheskie markery dolgosrochnykh effektov terapii u patsientov s sindromom myagkogo kognitivnogo snizheniya. Meditsinskii akademicheskii zhurnal 2019;19(1):84–86. Russian.